The Impact of Dose of Angiotensin-receptor Blocker Valsartan and Genetic Polymorphism on the Post-MI Ventricular Remodeling
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Angiotensin-converting enzyme inhibitors and angiotensin-receptor blocker valsartan
ameliorate ventricular remodeling after myocardial infarction (MI). Although the amount of
those drugs used in previous clinical trials, therefore recommended in practical guidelines
is maximum clinical dose, it has not been clearly demonstrated whether the recommended dose
is more efficacious compared to lower dose commonly used in clinical practice. In addition,
the impact of genetic polymorphism in neurohormonal system on the pharmacological effect has
not been explored in the setting of post-MI remodeling.
Therefore, the investigators evaluate whether submaximal dose, which are lower than those in
major pivotal trials but typically used in clinical practice, can offer similar benefit in
post-MI ventricular remodeling.